Learn how TORISEL may help you.
TORISEL was studied in a large clinical trial. Patients in this study had advanced renal cell carcinoma (RCC). They had not been treated with medications for advanced RCC before the study. The study compared TORISEL to a treatment called interferon-alpha.
Study results
The median overall survival for patients who got TORISEL was 49% higher than for those who got interferon-alpha (IFNα). This means patients who received TORISEL lived longer on average than patients who received IFNα. While TORISEL has been shown to extend survival, it is not a cure for advanced RCC.
Median overall survival in patients who got TORISEL compared to patients who got IFNα
Median overall survival was 10.9 months in the TORISEL group. It was 7.3 months in the IFNα group. This means:
Patients in the study stayed on the treatments for different amounts of time:
The most common side effects with TORISEL (occurring in 30% or more of patients) were:
Learn more about TORISEL Side Effects.
Study design
The study randomly divided 626 patients with advanced RCC into 3 groups:
The groups were similar in terms of age, gender, and race:
Risk factors
Patients included in the TORISEL study were expected to have a shorter survival than most advanced RCC patients. In order to enroll, patients were required to have at least 3 of the following 6 preselected prognostic risk factors:
Talk to your health care provider about risk factors and how they relate to treatment options.
Learn how TORISEL may help you.
TORISEL is indicated for the treatment of advanced renal cell carcinoma.
Patients should always ask their doctors for medical advice about adverse events.
You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where health care professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.